Novel Approaches for Diagnosis and Treatment of Pancreatic Cancer

Dear Colleagues,

Cancer can appear anywhere in the body, due to the accumulation of mutations and other genomic aberrations that lead to uncontrolled cell proliferation, inhibition of apoptosis, and an increased cell migration. Tumour cells are able to activate thorough mechanisms to generate a tumour from early stages and generate metastases through the induction of epithelial-to-mesenchymal transition, angiogenesis, and an immunosuppressive microenvironment. Other crucial events in tumourigenesis are the emergence of the undifferentiated phenotype and the generation and maintenance of cancer stem cells. In carcinogenesis, the co-activation of several genes and pathways is common, and the study of these factors and signalling pathways has greatly helped us to identify new targets for drug design. These drugs could be chemically synthesized or isolated from natural substances. These novel molecules could represent a massive step forward in reaching personalized medicine in the present clinical management of pancreatic cancer.

In this Special Issue entitled "Novel Approaches for Diagnosis and Treatment of Pancreatic Cancer", we encourage authors to submit high-quality research articles dealing with new diagnostic biomarkers and promising biomolecules that improve treatment response and survival and provide an outstanding rationale of their anti-tumour activity to the scientific and clinical community. This activity could be observed in both in vitro and/or in vivo models. In addition, we are open to receiving updated reviews about novel molecules with high potential to be used as diagnostic biomarkers or in the design of new treatment approaches.

Dr. Javier Martinez-Useros
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• pancreatic cancer
• small molecules
• monoclonal antibodies
• antibody-drug conjugated
• personalized therapy
• immunotherapy
• natural compounds
• exosomes
• nanoparticles
• biomarkers